Feb. 4 at 8:54 PM
AbbVie posted better-than-expected Q4 results, with adjusted earnings of
$2.71 per share versus the
$2.65 consensus, and revenue of
$16.6 billion, surpassing the
$16.4 billion forecast. The company also issued 2026 guidance of
$14.37–
$14.57 per share, exceeding analysts’ expectations.
Despite the strong performance, shares fell 4%, reflecting declines in specific portfolios. Oncology revenue reached
$1.7 billion, down 1.5–2.5%, while aesthetics—including Botox Cosmetic and Juvederm—fell about 1%. Humira revenue dropped 26% due to biosimilar competition, though it still beat estimates by roughly
$282 million.
Immunology products drove growth, with Skyrizi rising over 30% to
$5 billion and Rinvoq increasing nearly as much to
$2.4 billion. Analysts noted mixed results across portfolios and high Wall Street expectations as reasons for the stock’s drop. AbbVie also submitted applications to regulators for a new Rinvoq indication in non-segmental vitiligo, based on Phase 3 trial data.
$ABBV